Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Cardiogen and Livagen — mechanism, side effects, legal status, and pricing.
Cardiogen is a synthetic tetrapeptide (Ala-Glu-Asp-Arg / AEDR) from the Khavinson bioregulator series, studied in Russian preclinical models for potential effects on cardiac-tissue gene expression and cardiomyocyte structural proteins. Not FDA-approved; no Western clinical trials have been performed, and all published evidence originates from a single research group.
Livagen is a synthetic tetrapeptide (Lys-Glu-Asp-Ala / KEDA) from the Khavinson short-peptide 'bioregulator' series, developed at the St. Petersburg Institute of Bioregulation and Gerontology. Marketed in Russia primarily as a food-supplement-grade cytomax; not FDA-approved in the US; research-use only.
Cardiogen
Livagen
Category
Legal Status
Mechanism
Side Effects
Contraindications
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Cardiogen
Livagen
COA corpus from Disclosed Labs — independently tested batches only.
Cardiogen
10
COAs
99.5%
Avg purity
6
Labs
Livagen
9
COAs
99.6%
Avg purity
5
Labs
Evidence is limited to preclinical work from the Khavinson group at the St. Petersburg Institute of Bioregulation and Gerontology. Khavinson et al. (Bull Exp Biol Med, 2012; PMID 22977870) reported that H-Ala-Glu-Asp-Arg-OH increased expression of cytoskeletal and nuclear-matrix proteins in cultured mouse embryonic fibroblasts. There are no independently replicated studies, no randomized controlled trials, and no peer-reviewed evidence of clinical cardioprotective efficacy in humans.
Evidence base is essentially single-lab (Khavinson, Lezhava, and collaborators). In vitro studies on lymphocyte chromatin in elderly subjects and small Russian reports in chronic gastritis and immune senescence. No FDA-registered clinical trials and no Western RCTs.
Key references
Cardiogen (Recovery) and Livagen (Immune) are in different categories and target different biological pathways. This is a common pattern in multi-compound research protocols. Researchers should monitor the biomarkers from both profiles and watch for interactions listed in each compound’s contraindications. Consult a licensed healthcare provider before combining any research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Lab Testing
Disclosed Labs